Bioequivalence of two oral contraceptive drugs containing norethindrone and ethinyl estradiol.
Two oral contraceptive drugs, Formulation A and Formulation B, both of similar hormonal content, were compared with each other to determine if they were bioequivalent. Both drugs contain 1 mg of norethindrone (NET) and 0.035 mg of ethinyl estradiol (EE). Application of an interval test for the ratio of the computed parameter means demonstrated equivalence for the two formulations with respect to the 0-24 hour area under the plasma level versus time curve (AUC24), the total area under the curve (AUCtot) and for the maximum plasma concentration (Cmax) for both ethinyl estradiol and norethindrone. The data support the hypothesis for bioequivalence of the two formulations with respect to total absorption.
Saperstein
S
S
Syntex Laboratories, Inc., Palo Alto, CA.
Edgren
R A
RA
Lee
G J
GJ
Jung
D
D
Fratis
A
A
Kushinsky
S
S
Mroszczak
E
E
Dorr
A
A
D000328:Adult; D003277:Contraceptives, Oral, Combined / Q000493:pharmacokinetics; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008656:Mestranol / Q000493:pharmacokinetics*; D009640:Norethindrone / Q000097:blood / Q000493:pharmacokinetics*; D011863:Radioimmunoassay; D013810:Therapeutic Equivalency
D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D004997:Ethinyl Estradiol; C014715:Norinyl; D008656:Mestranol; D009640:Norethindrone